Interesting CVS Put And Call Options For January 2026

Stock Options Channel outlines two income-oriented option strategies on CVS (spot $79.21): selling the Jan 2026 $72 put for $0.50 would obligate purchase at $72 with an effective cost basis of $71.50 (≈9% OTM), carries a current 75% probability of expiring worthless and would generate a 0.69% return on cash committed (5.07% annualized YieldBoost). Alternatively, selling the Jan 2026 $87 covered call for $0.50 against shares bought today would cap upside at $87 for a 10.47% total return if called, is ≈10% OTM with a 74% chance to expire worthless and would add 0.63% (4.61% annualized) in YieldBoost. Implied vols are ~38–39% (puts/calls) versus a 33% trailing 12‑month realized volatility; Stock Options Channel will track the evolving odds and contract histories, highlighting the trade-off between generating modest income and capping upside.

Analysis

The Jan 2026 $72 put on CVS (spot $79.21) bids $0.50; selling-to-open obligates purchase at $72 with an effective cost basis of $71.50 before commissions and represents roughly a 9% discount to the current price. Stock Options Channel estimates a 75% probability the put will expire worthless, which would deliver a 0.69% return on the cash commitment or 5.07% annualized (YieldBoost).

Selling a Jan 2026 $87 covered call against shares bought at $79.21 would collect $0.50 and cap proceeds at $87, yielding a 10.47% total return if called and a 0.63% immediate premium (4.61% annualized) if the option expires worthless; the provider estimates a 74% probability of that outcome. Both contracts are roughly 9–10% out-of-the-money and carry modest income potential while exposing the seller to assignment risk and upside forfeiture.

Implied volatilities are ~38% on the put and 39% on the call versus a trailing 12‑month realized volatility of 33%, implying option premiums are priced above recent realized movement. These greeks-derived odds and the YieldBoost trade-off emphasize income generation at the expense of potential capital appreciation; probabilities and returns will change with volatility, price action, dividends and trading costs.

Key Decisions for Investors

• Consider selling the Jan 2026 $72 put only if you are willing to own CVS at an effective $71.50 per share and accept the roughly 25% chance of assignment, given the 0.69% (5.07% annualized) yield if it expires worthless
• If you already hold CVS, consider selling the Jan 2026 $87 covered call to capture a 0.63% income boost and potential 10.47% capped return to $87, recognizing that significant upside would be foregone if shares rally
• Monitor implied volatility and the option odds tracked by the provider—IV (38–39%) exceeds 12‑month realized vol (33%), so premium compression or vol spikes could materially change expected returns and assignment probabilities
• Limit position sizing or use protective hedges and include commissions/dividends in net-return calculations; reassess the strategy if quoted odds move materially from the current 74–75% range